Clinical trials: Platinum Resistance
Ovarian Serous Tumor, Recurrent Fallopian Tube Carcinoma
Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
This randomized phase II trial studies how well ATR kinase inhibitor M6620 (M6620) and gemcitabine hydrochloride work compared to standard treatment with gemcitabine hydrochloride alone in treating patients with ovarian, primary…
- Conditions
- Ovarian Serous Tumor, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Trial name
- NCT02595892
- Testing
- Berzosertib, Gemcitabine, Gemcitabine Hydrochloride
- Where
- 17 sites in United States
- Volunteers
- 70 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Cancer, Epithelial Ovarian Cancer
ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients
The purpose of this study is to determine how patients with ovarian, fallopian tube, and primary peritoneal cancer will best respond to treatment with rucaparib versus chemotherapy.
- Conditions
- Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Trial name
- NCT02855944
- Testing
- Chemotherapy, Rucaparib
- Where
- 77 sites in United States, Brazil and 10 more
- Volunteers
- 349 people
- Sponsor
- pharmaand GmbH
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma
Perfusion CT in Predicting Outcomes in Ovarian, Fallopian, or Peritoneal Cancer With Bevacizumab
This phase II trial studies how well computed tomography perfusion imaging works in predicting outcomes in patients with ovarian, fallopian tube, or primary peritoneal cancer who are receiving bevacizumab.
- Conditions
- Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Trial name
- NCT03412630
- Testing
- Computed Tomography Perfusion Imaging
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Ovarian Cancer, Fallopian Tube Cancer
Saracatinib and Paclitaxel in Platinum-resistant Ovarian Cancer
The purpose of this study is to investigate whether the addition of the Src inhibitor saracatinib (AZD0530) to weekly paclitaxel improves efficacy, compared with paclitaxel plus placebo, in patients with relapsed…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- SaPPrOC (NCT01196741)
- Testing
- Paclitaxel, Saracatinib
- Where
- 12 sites in United Kingdom
- Volunteers
- 107 people
- Sponsor
- University College, London
Ovarian Cancer, Fallopian Tube Cancer
A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208)
This trial will study tisotumab vedotin to find out what its side effects are and to see if it works for platinum-resistant ovarian cancer (PROC).
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Trial name
- NCT03657043
- Testing
- tisotumab vedotin
- Where
- 37 sites in United States, Belgium and 4 more
- Volunteers
- 98 people
- Sponsor
- Seagen Inc.
Ovarian Cancer, Peritoneal Cavity Cancer
Lapatinib and Topotecan in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Did Not Respond to Cisplatin or Carboplatin
RATIONALE: Lapatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as topotecan, work in different ways to stop the growth of tumor cells, either by…
- Trial name
- NCT00436644
- Testing
- Lapatinib, Topotecan
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- Mayo Clinic
Platinum-resistant Ovarian Cancer
Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian
Afuresertib is an AKT inhibitor, a new class of agents under development that may provide physicians with a new clinical option to control platinum resistant ovarian cancer (PROC) progression.
- Trial name
- PROFECTA-II (NCT04374630)
- Testing
- Paclitaxel, Afuresertib
- Where
- 47 sites in United States, China
- Volunteers
- 150 people
- Sponsor
- Laekna Limited
Platinum-resistant Ovarian Cancer, Platinum-resistant Fallopian Cancer
Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian or Peritoneal Cancer
This 2-part, Phase 1/2 study will test investigational cancer drugs known as CRS-207, epacadostat (IDO), and pembrolizumab (pembro).
- Conditions
- Platinum-resistant Ovarian Cancer, Platinum-resistant Fallopian Cancer, Platinum-resistant Peritoneal Cancer
- Trial name
- SEASCAPE (NCT02575807)
- Testing
- CRS-207, Epacadostat, Pembrolizumab
- Where
- 12 sites in United States, Canada
- Volunteers
- 35 people
- Sponsor
- Aduro Biotech, Inc.
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma
Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
This phase II trial studies how well Avatar-directed chemotherapy works in treating patients with ovarian, primary peritoneal, or fallopian tube cancer that does not respond to platinum anti-cancer drugs.
- Conditions
- Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Trial name
- NCT02312245
- Testing
- Bevacizumab, Gemcitabine Hydrochloride, Paclitaxel
- Where
- 3 sites in United States
- Volunteers
- 13 people
- Sponsor
- Mayo Clinic
Recurrent Platinum Resistant Epithelial Ovarian Carcinoma, Recurrent Epithelial Endometrial Carcinoma
Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas
Background: Cancers of the female reproductive organs often come back after treatment. A drug called sacituzumab govitecan (SG) has been approved for use in other types of cancers.
- Conditions
- Recurrent Platinum Resistant Epithelial Ovarian Carcinoma, Recurrent Epithelial Endometrial Carcinoma, Recurrent Epithelial Cervical Carcinoma
- Trial name
- NCT06865677
- Testing
- Sacituzumab Govitecan, EKG, Brain MRI
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Cancer
A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)
This is a Phase 1b/2 dose-optimization study to evaluate safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of avelumab (MSB0010718C) in combination with other cancer immunotherapies in patients with…
- Trial name
- NCT02554812
- Testing
- Avelumab, Utomilumab, PF-04518600
- Where
- 88 sites in United States, Australia and 6 more
- Volunteers
- 409 people
- Sponsor
- Pfizer
Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma
Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This randomized phase I/IIb trial studies side effects and best dose of atezolizumab when given together with guadecitabine and CDX-1401 vaccine and to see how well they work in treating patients with ovarian, fallopian tube, or…
- Conditions
- Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Carcinoma
- Trial name
- NCT03206047
- Testing
- Atezolizumab, DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Guadecitabine
- Where
- 17 sites in United States
- Volunteers
- 9 people
- Sponsor
- National Cancer Institute (NCI)